221 related articles for article (PubMed ID: 22015149)
41. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
[TBL] [Abstract][Full Text] [Related]
42. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.
Lee ES; Heller MM; Kamangar F; Park KK; Koo JY
J Drugs Dermatol; 2012 Mar; 11(3):413-4. PubMed ID: 22395596
[TBL] [Abstract][Full Text] [Related]
43. Our experience with etanercept in the treatment of psoriasis.
Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
[TBL] [Abstract][Full Text] [Related]
44. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
45. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
46. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis.
Paul C; Stalder JF; Thaçi D; Vincendon P; Brault Y; Kielar D; Tebbs V
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):448-55. PubMed ID: 21557778
[TBL] [Abstract][Full Text] [Related]
47. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
48. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
50. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.
Ortonne JP; Taïeb A; Ormerod AD; Robertson D; Foehl J; Pedersen R; Molta C; Freundlich B
Br J Dermatol; 2009 Nov; 161(5):1190-5. PubMed ID: 19566665
[TBL] [Abstract][Full Text] [Related]
51. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
[TBL] [Abstract][Full Text] [Related]
52. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
53. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Langley RG; Papp K; Gottlieb AB; Krueger GG; Gordon KB; Williams D; Valdes J; Setze C; Strober B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1252-61. PubMed ID: 23157612
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
Nestorov I; Zitnik R; DeVries T; Nakanishi AM; Wang A; Banfield C
Br J Clin Pharmacol; 2006 Oct; 62(4):435-45. PubMed ID: 16995864
[TBL] [Abstract][Full Text] [Related]
55. A randomized trial of etanercept as monotherapy for psoriasis.
Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R
Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082
[TBL] [Abstract][Full Text] [Related]
56. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
57. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
[TBL] [Abstract][Full Text] [Related]
58. Subgroup analyses of etanercept in pediatric patients with psoriasis.
Paller AS; Eichenfield LF; Langley RG; Leonardi CL; Siegfried EC; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Aug; 63(2):e38-41. PubMed ID: 20633781
[No Abstract] [Full Text] [Related]
59. Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
van Lümig PP; Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):283-91. PubMed ID: 21435026
[TBL] [Abstract][Full Text] [Related]
60. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]